Capozide 25/15 and Latanoprost

• Generic Name: captopril / hydrochlorothiazide
• Dosage Forms: n.a.
• Other Brand Names: Capozide 25/15, Capozide 25/25, Capozide 50/15, Capozide 50/25

Captopril and hydrochlorothiazide combination is used to treat high blood pressure (hypertension). High blood pressure adds to the work load of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys resulting in a stroke, heart failure, or kidney failure. Hypertension may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled .

Captopril works by blocking an enzyme in the body that is necessary to produce a substance that causes blood vessels to tighten. As a result, the blood vessels relax. Hydrochlorothiazide works by helping reduce the amount of salt and water in the body by acting on the kidneys to increase the flow of urine. Both of these medicines lower blood pressure and increase the supply of blood and oxygen to the heart .

This medicine is available only with your doctor's prescription .

• Generic Name: latanoprost ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Xalatan, Xelpros, Xalatan Multi-Pack

Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. One of several first-line agents to reduce elevated IOP.

Safety and efficacy not established for the treatment of angle-closure, inflammatory, or neovascular glaucoma.

Appears to be more effective than unoprostone, as effective as travoprost, and slightly less effective than bimatoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension.

May be more effective or at least as effective as twice daily administration of timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Appears to be more effective than thrice-daily administration of dorzolamide 2%.

May be used in conjunction with a topical β-adrenergic blocking agent (e.g., betaxolol, carteolol, levobunolol, metipranolol, timolol), topical dipivefrin, topical epinephrine, an oral carbonic anhydrase inhibitor (e.g., acetazolamide), or a topical carbonic anhydrase inhibitor (e.g., dorzolamide).

Tolerance does not occur, and reduction in mean IOP is maintained for up to at least 24 months of therapy after initial stabilization.